tumor-infiltrating lymphocytes

[Journal of Clinical Investigation] Investigators observed that anti–PD-1 therapy depends on IL-2 signaling, which raised the possibility that a lack of IL-2 limited anti–PD-1–induced effector T cell expansion.

[Molecular Therapy-Oncolytics] The authors provide an overview of current and on-going chimeric antigen receptor (CAR) T cell clinical studies in pancreatic cancer and the major challenges and strategies to improve CAR T cell efficacy.

[Science Advances] Six candidates among the most commonly shared HLA-A2 epitopes with evidence of translation were selected for immunological evaluation. In vitro priming assays confirmed the immunogenicity of these epitopes, which induced high-avidity CD8+ T cell clones.

[Biomedicine & Pharmacotherapy] The development of biomarkers is important for monitoring the effect of treatment, assessing the patient's response to immune checkpoint inhibitors, determining adverse reactions, and predicting the direction of disease development.

[Cancer Research] Investigators quantified tumor infiltration across two distinct clear cell renal cell carcinoma patient tumor cohorts using complementarity determining region-3 (CDR3) sequence recovery counts in tumor-infiltrating lymphocytes and a generalized diversity index for CDR3 sequence distributions.

[Molecular Therapy Oncolytics] Non-viral/plasmid-based programmed cell death protein 1 (PD-1) knockout was carried out immediately prior to the traditional 14-day tumor-infiltrating lymphocytes-based ACT rapid expansion protocol.